Trials / Completed
CompletedNCT01839214
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis
A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects With Mild to Moderate Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety and efficacy in subjects with mild to moderate ulcerative colitis, as measured by Modified Mayo Score, Modified Baron Score, IBDQ, calprotectin and other assessments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB-201 160mg | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2013-04-24
- Last updated
- 2015-03-27
Locations
3 sites across 3 countries: Bulgaria, Hungary, Poland
Source: ClinicalTrials.gov record NCT01839214. Inclusion in this directory is not an endorsement.